HCID 86691838, compound → HCID 86691840, compound
Reaction equation
[CH3:1][C:2]([CH3:26])([CH3:25])[CH2:3][N:4]1[C:12]2[C:7](=[N:8][C:9]([C:13]3[CH:20]=[C:19]([CH:21]=[O:22])[CH:18]=[CH:17][C:14]=3[C:15]#[N:16])=[CH:10][CH:11]=2)[N:6]([CH3:23])[C:5]1=[O:24].[CH3:27][Mg]Br>C1COCC1.CO>[CH3:1][C:2]([CH3:26])([CH3:25])[CH2:3][N:4]1[C:12]2[C:7](=[N:8][C:9]([C:13]3[CH:20]=[C:19]([C@@H:21]([OH:22])[CH3:27])[CH:18]=[CH:17][C:14]=3[C:15]#[N:16])=[CH:10][CH:11]=2)[N:6]([CH3:23])[C:5]1=[O:24]Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 2
Conditions
- Temperature
- -78 °C
Procedure
To a round bottom flask, 2-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]-4-formylbenzonitrile (30-1) (70 mg, 0.2 mmol) was added under nitrogen, dissolved in THF (1 mL), and cooled to −78° C. 3M methylmagnesium bromide (0.08 ml, 0.24 mmol) was added slowly to the cooled solution and allowed to stir for 30 minutes. The reaction was warmed to room temperature for 30 minutes until complete conversion over starting material. The mixture was diluted with methanol, and passed through a syringe filter. The solution was purified using reverse phase chromatography (10-100%, 0.1% TFA in H2O/Acetonitrile) and the desired fractions were collected and concentrated to produce 2-[1-(2,2-dimethylpropyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-5-yl]-4-[(1S)-1-hydroxyethyl]benzonitrile (30-2). HRMS (M+H)+: observed=365.1976, calculated=365.1972.
Workup
- temperatureThe reaction was warmed to room temperature for 30 minutes until complete conversion
- custompassed through a syringe
- filtrationfilter
- customThe solution was purified
- customthe desired fractions were collected
- concentrationconcentrated
Sources & evidence
- ORD record
- ord-e76a04a3ac6b477c85cb9bb41bd54f46
- Source dataset
- uspto-grants-2014_07
- Patent number
- US08765784B2
Reaction notes
Loading…